Immune Checkpoint Inhibitor Therapy in Cancer: Success versus Limitations

被引：1

作者：

Sarder, Amit ^{[1
]}

Mia, Md. Babu ^{[2
]}

Sarkar, Antara ^{[1
]}

Mandal, Chanchal ^{[1
]}

机构：

[1] Khulna Univ, Biotechnol & Genet Engn Discipline, Khulna 9208, Bangladesh

[2] Icahn Sch Med, Dept Hematol & Oncol, Mt Sinai, NY 10029 USA

来源：

BIOMEDICAL RESEARCH AND THERAPY | 2022年 / 9卷 / 12期

关键词：

Immune Checkpoint Inhibitor; T-cell; Immunotherapy; Cancer; Tumor; T-CELL DYSFUNCTION; PREDICTIVE BIOMARKERS; MOLECULAR-BASIS; LUNG-CANCER; IMMUNOTHERAPY; PD-1; BLOCKADE; CTLA-4; ANTICANCER; MANAGEMENT;

D O I：

10.15419/bmrat.v9i12.784

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The immune system possesses the capability to identify tumor cells and eradicate early malignant tumor cells. Thus, activating the immune system of cancer patients provides great therapeutic ben-efits. Inhibitory T-cell immune checkpoints playa vital role in tumor immune escape. Thus, immune checkpoint inhibitors (ICIs) have attracted attention in cancer immunotherapy. In ICI therapy, the therapeutic targets are the expressed immune checkpoints of T cells. Immune checkpoints induce T-cell dysfunction in cancer. However, ICIs or immunomodulators restore the antitumor actions of cytotoxic T cells by blocking immune checkpoints. ICIs have become desirable treatment options because of their broad range of activities and response rates ranging from 15% to 90% in several cancer types. Generally, ICIs also have favorable toxicity profiles. This paper will first delve deeper into the best-known immune checkpoints and then review ICIs that are attractive treatment op-tions in immunotherapy.

引用

页码：5455 / 5464

页数：10

共 87 条

[1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].